Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Liver Diseases

Free Subscription Articles published in Lancet Retrieve available abstracts of 43 articles: HTML format

Single Articles

December 2025
1. SCHOENFELD JD, Haas-Kogan DA, O'Neill AF
   Abscopal response in a patient with fibrolamellar hepatocellular carcinoma following radiotherapy.
   Lancet. 2025;404:2603-2604.
   PubMed    
   
   
   November 2025
2. GALLE PR, Yau T, Decaens T
   Treatments for unresectable hepatocellular carcinoma: insights from CheckMate 9DW - Authors' reply.
   Lancet. 2025;406:2423-2424.
   PubMed    
   
   
   
3. SHI R, Li J, Zhang L
   Treatments for unresectable hepatocellular carcinoma: insights from CheckMate 9DW.
   Lancet. 2025;406:2422-2423.
   PubMed    
   
   
   
4. SANTHOSH A, Sreenath ND
   Treatments for unresectable hepatocellular carcinoma: insights from CheckMate 9DW.
   Lancet. 2025;406:2421-2422.
   PubMed    
   
   
   
5. NOUREDDIN M, Harrison SA, Loomba R, Alkhouri N, et al
   Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study.
   Lancet. 2025 Nov 11:S0140-6736(25)02114-2. doi: 10.1016/S0140-6736(25)02114.
   PubMed     Abstract available
   
   
   October 2025
6. WANG Z, Fan J, Zhou S, Sun Y, et al
   Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial.
   Lancet. 2025 Oct 19:S0140-6736(25)01720-9. doi: 10.1016/S0140-6736(25)01720.
   PubMed     Abstract available
   
   
   
7. KASEB A, Pawlik TM
   Perioperative camrelizumab plus rivoceranib versus surgery in resectable hepatocellular carcinoma.
   Lancet. 2025 Oct 19:S0140-6736(25)02104-X. doi: 10.1016/S0140-6736(25)02104.
   PubMed    
   
   
   August 2025
8. LOOMBA R, Morgan E, Yousefi K, Li D, et al
   Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): results of a 51-week, multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
   Lancet. 2025;406:821-831.
   PubMed     Abstract available
   
   
   
9. NOUREDDIN M, Frias JP, Neff GW, Lucas KJ, et al
   Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial.
   Lancet. 2025;406:719-730.
   PubMed     Abstract available
   
   
   
10. KUDO M, Ren Z, Finn RS, Llovet JM, et al
    Clinical, ethical, and quality-of-life outcomes in unresectable hepatocellular carcinoma: the LEAP-012 trial - Authors' reply.
    Lancet. 2025;406:694.
    PubMed    
    
    
    
11. ONDER AH
    Clinical, ethical, and quality-of-life outcomes in unresectable hepatocellular carcinoma: the LEAP-012 trial.
    Lancet. 2025;406:693.
    PubMed    
    
    
    
12. SHERRY AD, Dudzinski SO, Ludmir EB
    Clinical, ethical, and quality-of-life outcomes in unresectable hepatocellular carcinoma: the LEAP-012 trial.
    Lancet. 2025;406:693-694.
    PubMed    
    
    
    July 2025
13. CHAN SL, Sun HC, Xu Y, Zeng H, et al
    The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment.
    Lancet. 2025 Jul 25:S0140-6736(25)01042-6. doi: 10.1016/S0140-6736(25)01042.
    PubMed    
    
    
    May 2025
14. VITHAYATHIL M, Sharma R
    Nivolumab plus ipilimumab in hepatocellular carcinoma.
    Lancet. 2025 May 7:S0140-6736(25)00417-9. doi: 10.1016/S0140-6736(25)00417.
    PubMed    
    
    
    
15. YAU T, Galle PR, Decaens T, Sangro B, et al
    Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial.
    Lancet. 2025 May 7:S0140-6736(25)00403-9. doi: 10.1016/S0140-6736(25)00403.
    PubMed     Abstract available
    
    
    February 2025
16. RAHIM MN, Williamson C, Kametas NA, Heneghan MA, et al
    Pregnancy and the liver.
    Lancet. 2025;405:498-513.
    PubMed     Abstract available
    
    
    January 2025
17. REITER FP, Geier A
    TACE plus immune checkpoint inhibitor-based systemic therapies for hepatocellular carcinoma.
    Lancet. 2025 Jan 8:S0140-6736(24)02680-1. doi: 10.1016/S0140-6736(24)02680.
    PubMed    
    
    
    
18. SANGRO B, Kudo M, Erinjeri JP, Qin S, et al
    Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.
    Lancet. 2025 Jan 8:S0140-6736(24)02551-0. doi: 10.1016/S0140-6736(24)02551.
    PubMed     Abstract available
    
    
    
19. KUDO M, Ren Z, Guo Y, Han G, et al
    Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study.
    Lancet. 2025 Jan 8:S0140-6736(24)02575-3. doi: 10.1016/S0140-6736(24)02575.
    PubMed     Abstract available
    
    
    November 2024
20. ISRAELSEN M, Francque S, Tsochatzis EA, Krag A, et al
    Steatotic liver disease.
    Lancet. 2024;404:1761-1778.
    PubMed     Abstract available
    
    
    October 2024
21. PONVILAWAN B, Roth MT
    Combination strategies in advanced hepatocellular carcinoma: the CARES-310 trial.
    Lancet. 2024;404:1405.
    PubMed    
    
    
    
22. QIN S
    Combination strategies in advanced hepatocellular carcinoma: the CARES-310 trial - Author's reply.
    Lancet. 2024;404:1405-1406.
    PubMed    
    
    
    
23. WANG JK, Liao R
    Combination strategies in advanced hepatocellular carcinoma: the CARES-310 trial.
    Lancet. 2024;404:1404-1405.
    PubMed    
    
    
    
24. LI H, Yan J, Han T
    Combination strategies in advanced hepatocellular carcinoma: the CARES-310 trial.
    Lancet. 2024;404:1403-1404.
    PubMed    
    
    
    September 2024
25. ADAM R, Piedvache C, Chiche L, Adam JP, et al
    Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial.
    Lancet. 2024;404:1107-1118.
    PubMed     Abstract available
    
    
    
26. HEINEMANN V, Stintzing S
    Liver transplantation in metastatic colorectal cancer: a new standard of care?
    Lancet. 2024;404:1078-1079.
    PubMed    
    
    
    
27. TANAKA A, Ma X, Takahashi A, Vierling JM, et al
    Primary biliary cholangitis.
    Lancet. 2024;404:1053-1066.
    PubMed     Abstract available
    
    
    August 2024
28. MAIWALL R, Kulkarni AV, Arab JP, Piano S, et al
    Acute liver failure.
    Lancet. 2024;404:789-802.
    PubMed     Abstract available
    
    
    
29. CHOW PKH, Hack SP, Spahn JH, Yopp AC, et al
    Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial - Authors' reply.
    Lancet. 2024;404:657-658.
    PubMed    
    
    
    
30. ROSE S, Ashraf MU, Premkumar M
    Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial.
    Lancet. 2024;404:656-657.
    PubMed    
    
    
    
31. CHEN Z, Lan X, Du C, Xiao H, et al
    Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial.
    Lancet. 2024;404:656.
    PubMed    
    
    
    
32. DONADON M, Di Martino M, Rigamonti C
    Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial.
    Lancet. 2024;404:655-656.
    PubMed    
    
    
    
33. SHIN H, Lee JH
    Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial.
    Lancet. 2024;404:654-655.
    PubMed    
    
    
    June 2024
34. ENG C, Yoshino T, Ruiz-Garcia E, Mostafa N, et al
    Colorectal cancer.
    Lancet. 2024 Jun 20:S0140-6736(24)00360-X. doi: 10.1016/S0140-6736(24)00360.
    PubMed     Abstract available
    
    
    May 2024
35. DE OLIVEIRA FRANCO A, Uberti Dos Santos V, von Ameln Lovison O, Zavascki AP, et al
    Invasive liver abscess syndrome with central nervous system involvement caused by hypermucoviscous Klebsiella pneumoniae: positive string test.
    Lancet. 2024;403:2257-2258.
    PubMed    
    
    
    April 2024
36. KARLSEN TH, Rutter H, Carrieri P, Zelber-Sagi S, et al
    The EASL-Lancet Commission on liver health in Europe: prevention, case-finding, and early diagnosis to reduce liver-related mortality.
    Lancet. 2024;403:1522-1524.
    PubMed    
    
    
    November 2023
37. VON KODOLITSCH Y, Kubisch C, Carrel T
    AATD as a genetic risk factor for aneurysmal disease - Authors' reply.
    Lancet. 2023;402:1626.
    PubMed    
    
    
    
38. KUEPPERS F
    AATD as a genetic risk factor for aneurysmal disease.
    Lancet. 2023;402:1625-1626.
    PubMed    
    
    
    October 2023
39. VOGEL A, Meyer T, Saborowski A
    IMbrave050: the first step towards adjuvant therapy in hepatocellular carcinoma.
    Lancet. 2023 Oct 23:S0140-6736(23)01962-1. doi: 10.1016/S0140-6736(23)01962.
    PubMed    
    
    
    
40. QIN S, Chen M, Cheng AL, Kaseb AO, et al
    Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
    Lancet. 2023 Oct 20:S0140-6736(23)01796-8. doi: 10.1016/S0140-6736(23)01796.
    PubMed     Abstract available
    
    
    September 2023
41. PINATO DJ, D'Alessio A, Celsa C, Manfredi GF, et al
    The price and value of therapeutic synergy in liver cancer.
    Lancet. 2023;402:1108-1110.
    PubMed    
    
    
    
42. TAPPER EB, Serper M
    Screening for advanced liver disease in the general population.
    Lancet. 2023;402:941-943.
    PubMed    
    
    
    
43. SERRA-BURRIEL M, Juanola A, Serra-Burriel F, Thiele M, et al
    Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study.
    Lancet. 2023;402:988-996.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.